logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

XUNLONG SCITECH (06715) will distribute an interim dividend of 0.75 yuan per share.

date
17:35 24/08/2026
avatar
GMT Eight
Sturgeon Dragon Technology (06715) announced that it will distribute a mid-term dividend of 0.75 yuan per share for the first half of 2026.
XUNLONG SCITECH (06715) announced that it will distribute an interim dividend of RMB 0.75 per share for the first half of 2026.
Related Articles
HK Stock
AV CONCEPT HOLD (00595) spent HKD 1.294 million to repurchase 1 million shares on August 24.
HK Stock
LEAPMOTOR (09863) announced its interim results, with a profit attributable to shareholders of 208 million yuan, a year-on-year increase of 530.97%.
HK Stock
BAO PHARMA-B (02659): The clinical trial application for KJ015 injection (anti-HER2 bispecific antibody subcutaneous formulation) has been approved by the US FDA.
AV CONCEPT HOLD (00595) spent HKD 1.294 million to repurchase 1 million shares on August 24.
HK Stock
LEAPMOTOR (09863) announced its interim results, with a profit attributable to shareholders of 208 million yuan, a year-on-year increase of 530.97%.
HK Stock
BAO PHARMA-B (02659): The clinical trial application for KJ015 injection (anti-HER2 bispecific antibody subcutaneous formulation) has been approved by the US FDA.
HK Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.